Nature Cancer May issue cover

Cycling back to folate metabolism in cancer

  • Younghwan Lee
  • Karen H. Vousden
  • Marc Hennequart
Review Article

Announcements

  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

    • At present, six CAR-T therapies are FDA approved to treat hematological cancers, but not all patients respond. A new study has developed a multidimensional functional profiling method to screen CAR-T cells from patients with large B cell lymphomas in clinical trials and identified a T cell subset associated with successful clinical response.

      • Kevin P. Letscher
      • Sai T. Reddy
      News & Views
    • Tumor fibrosis is known to suppress anti-tumor immunity. A new study now highlights the role of tumor-associated macrophages in coordinating fibrosis-mediated metabolic changes in tumors, restricting cytotoxic T cell responses and contributing to tumor growth.

      • Matthew D. Perricone
      • Costas A. Lyssiotis
      News & Views
    • T cell receptor (TCR)-engineered T cells offer great promise for targeting tumor antigens in cancer therapy. A synthetic fusion protein termed 80BB, which can simultaneously activate the CD28 and 4-1BB co-stimulatory pathways, is now shown to enhance overall functionality of therapeutic TCR/CD3-dependent T cells in an antigen-agnostic manner.

      • Julia Höbart
      • Jürgen Ruland
      News & Views
    • Targeted therapies that use small-molecule inhibitors for the treatment of T cell blood cancer exist only for certain subtypes, and the development of immunologically based CAR T cell therapies has been challenging. A study now exploits the fact that malignant T cells express one of two T cell receptor-β variants and investigates strategies for targeting these malignant cells while sparing half of the non-malignant T cells.

      • Charles E. de Bock
      • Jan Cools
      News & Views
    • Gemcitabine is a widely used chemotherapy drug that acts by targeting DNA replication. Understanding why many tumors are unresponsive to gemcitabine is a clinical challenge. A new study in Nature Cancer reports that upregulation of the cytidine deaminases APOBEC3C and APOBEC3D facilitates resistance to gemcitabine by protecting cells against DNA replication stress.

      • John Maciejowski
      • Taha Mohamed
      News & Views
  • As quantum technology advances, it holds immense potential to accelerate oncology discovery through enhanced molecular modeling, genomic analysis, medical imaging, and quantum sensing.

    • Siddhi Ramesh
    • Teague Tomesh
    • Alexander T. Pearson
    Comment
  • Johanna Joyce received her PhD from the University of Cambridge, and did postdoctoral research at the University of California, San Francisco. She then joined the faculty at Memorial Sloan Kettering Cancer Center, New York, becoming a tenured member in 2014. She moved to Switzerland in 2016, where she later served as the inaugural executive director of the Agora Cancer Center Lausanne. She is currently a member of the Ludwig Institute for Cancer Research and a professor at the University of Lausanne.

    • Johanna A. Joyce
    Turning Points
  • Gold-standard cancer data management is pivotal to enable precision medicine for European citizens. Achieving this goal relies on key elements: adopting standardized data formats, ensuring robust data privacy, educating professionals about the infrastructure’s benefits and leveraging cutting-edge technologies to transform cancer care.

    • Macha Nikolski
    • Eivind Hovig
    • Gary Saunders
    Comment
  • Drug regulatory agencies in the USA and Europe have mechanisms to provide patients faster access to novel treatments, expecting that follow-up trials will confirm clinically meaningful results. However, some early approvals are subsequently withdrawn. Here we discuss the insights gained from withdrawn accelerated approvals for oncologic agents in the past decade.

    • George S. Mellgard
    • Tito Fojo
    • Susan E. Bates
    Comment
  • Anirban Maitra obtained his medical degree from the All India Institute of Medical Sciences, New Delhi, in 1996; this was followed by residency and fellowships in pathology at the University of Texas Southwestern Medical Center, Dallas, and Johns Hopkins University School of Medicine, Baltimore. From 2002 to 2013, he served as faculty in the departments of pathology and oncology at Johns Hopkins, before being recruited to the MD Anderson Cancer Center as Professor of Pathology and Translational Molecular Pathology and Scientific Director of the Sheikh Ahmed Center for Pancreatic Cancer Research.

    • Anirban Maitra
    Turning Points

Nature Careers

Science jobs

  • Endowed Chair in Macular Degeneration Research

    Dallas, Texas (US)

    The University of Texas Southwestern Medical Center (UT Southwestern Medical Center)

  • Postdoctoral Fellow

    Postdoc positions on ERC projects – cellular stress responses, proteostasis and autophagy

    Frankfurt am Main, Hessen (DE)

    Goethe University (GU) Frankfurt am Main - Institute of Molecular Systems Medicine

  • ZJU 100 Young Professor

    Promising young scholars who can independently establish and develop a research direction.

    Hangzhou, Zhejiang, China

    Zhejiang University

  • Qiushi Chair Professor

    Distinguished scholars with notable achievements and extensive international influence.

    Hangzhou, Zhejiang, China

    Zhejiang University

  • Research Postdoctoral Fellow - MD

    Houston, Texas (US)

    Baylor College of Medicine (BCM)

Advertisement